Eurofins Scientific SE

SWX:ESF Stock Report

Market Cap: CHF 11.3b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Eurofins Scientific Past Earnings Performance

Past criteria checks 2/6

Eurofins Scientific has been growing earnings at an average annual rate of 35.4%, while the Life Sciences industry saw earnings growing at 17.6% annually. Revenues have been growing at an average rate of 17.1% per year. Eurofins Scientific's return on equity is 12.5%, and it has net margins of 8.7%.

Key information

35.4%

Earnings growth rate

33.4%

EPS growth rate

Life Sciences Industry Growth17.6%
Revenue growth rate17.1%
Return on equity12.5%
Net Margin8.7%
Last Earnings Update31 Dec 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Eurofins Scientific makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SWX:ESF Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 226,7125811420
30 Sep 226,7856121310
30 Jun 226,8576431380
31 Mar 226,7876961350
31 Dec 216,7187491150
30 Sep 216,5537871170
30 Jun 216,3888251200
31 Mar 215,9136651200
31 Dec 205,4395051190
30 Sep 205,0793471200
30 Jun 204,7191901200
31 Mar 204,6411681190
31 Dec 194,5631461170
30 Sep 194,3841441110
30 Jun 194,2051431060
31 Mar 193,993159980
31 Dec 183,781175900
30 Sep 183,549182820
30 Jun 183,318190750
31 Mar 183,145185620
31 Dec 172,971179480
30 Sep 172,848166420
30 Jun 172,725152350
31 Mar 172,631145370
31 Dec 162,537138380
30 Sep 162,427104350
30 Jun 162,31769320

Quality Earnings: ESF has high quality earnings.

Growing Profit Margin: ESF's current net profit margins (8.7%) are lower than last year (11.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ESF's earnings have grown significantly by 35.4% per year over the past 5 years.

Accelerating Growth: ESF's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: ESF had negative earnings growth (-22.4%) over the past year, making it difficult to compare to the Life Sciences industry average (9.6%).

Return on Equity

High ROE: ESF's Return on Equity (12.5%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/05/21 23:10
End of Day Share Price 2023/02/21 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Eurofins Scientific SE is covered by 35 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ankush KathuriaAlphaValue
Pierre-Yves GauthierAlphaValue
Hubert D'AillieresBanco BPI, S.A.